Global WholeHealth Partners with Healgen Scientific to Sell FDA EUA Authorized SARS-COV-2 IgG/IgM Antibody Whole Blood, Serum and Plasma Rapid Test as Mentioned in the August 4th, 2020 8K Filing
SAN CLEMENTE, CA, Aug. 11, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE ‒ Global WholeHealth Partners Corp. (OTC PINK: GWHP) announced today that it is authorized to sell FDA EUA Authorized SARS-COV-2 IgG/IgM Antibody Whole Blood, Serum and Plasma Rapid Test.
Mr. Charles Strongo, the Chairman and CEO of Global WholeHealth Partners Corp., said, "The Company's goal is to offer the fastest and most reliable in-vitro diagnostic tests on the market, while keeping ahead in R&D, by offering FDA Approved Troponin I Whole Blood, Influenza A & B, and Strep A. The Company also has international testing, which is not sold in the USA, with an FDA Certificate of Exportability (2260-11-2019) for tests like Rapid Ebola, Rapid Dengue Fever Antibody, and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests." Global is planning to be able to offer an Antigen Rapid Test soon.”
The SARS-COV-2 IgG/IgM Antibody Whole Blood, Serum and Plasma Rapid Test is a fast qualitative detection and differentiation of lgM and lgG antibodies against SARS-CoV-2 in human whole blood, serum and plasma.
Intended Use:
The COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is a lateral flow immunoassay intended for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human venous whole blood, plasma from anticoagulated blood (Li+ heparin, K2EDTA, and sodium citrate), or serum. The COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.
Call 1-877-568-GWHP (4947) to become a distributor or buy FDA EUA Authorized SARS-COV-2 IgG/IgM Antibody Whole Blood, Serum and Plasma Rapid Test kits.
About Global WholeHealth Partners Corp.:
Global WholeHealth Partners Corp. provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines that detect in about 90 minutes and Rapid Diagnostic Testing (RDT) Serum Plasma and Whole Blood that detect between 10-15 minutes, which predict diseases ahead of its industry competitors.
By so doing, GWHP has led the fight against vector-borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector-borne diseases. Our vision is to lead the industry in infectious disease diagnostics and provide molecular solutions that lessen the time to diagnose medical results and empower healthcare professionals. For more details: https://gwhpcorp.com
Forward-Looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Media Contact:
Name: Charles Strongo,
CEO, Global WholeHealth Partners Corp.
Email: investors@gwhpcorp.com
